Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — Shareholder Meeting (December 2016)
12 slides from Mach7 Technologies's shareholder meeting presentation, Dec 7, 2016
Slide 1: Mach7 Technologies Limited AGM Presentation
MACH7 TECHNOLOGIES LIMITED AGM PRESENTATION, M7T.ASX 7 DECEMBER 2016 Copyright © 2013 Mach7 Technologies Copyright © 2013 Mach7 Technologies
Slide 2: Company Overview
COMPANY OVERVIEW Top tier Board and management team with a high quality shareholder base Financial information ($A) Board Share price (5-Dec-16) $0.041 Damien Lim Dr Nigel Finch Non-Executive Chairman Non-Executive Director Number of shares (m)1 1,087.5 Mr Lim has 21+ years in equity and investment
Slide 3: Core Technology
CORE TECHNOLOGY Mach7 offers the best-in-class Enterprise Imaging Platform that comprises four core modular components that can be deployed independently or as an integrated solution. Building blocks of Patented technology Enterprise Imaging Platform 3 Copyright © 2013 Mach7 Technologies
Slide 4: The Mach7 Solution
THE MACH7 SOLUTION Mach7 Enterprise Imaging Platform is a highly scalable and robust solution that can be deployed across clinical enterprise for varying facilities of all types and sizes Deployment Options Customer selects Mach7 Enterprise Imaging Platform, the best-in-class Cloud Onsite software,
Slide 5: Customer Evolution
CUSTOMER EVOLUTION Mach7’s global customer base is progressing from earlier adopters towards mid-market 529 Installed sites, across… 11 Countries 47 Unique customers, comprising… 34 Hospital 8 Imaging centres 5 Other (eg. Telstra) Early customers – academic medical centres Mid-market opportunities –
Slide 6: Market Opportunity
MARKET OPPORTUNITY Mach7 has a US$3.8 billion+ addressable market with the ability to compete across numerous market segments – PACS replacement underway Mach7 market opportunity Conversion to an enterprise imaging based platform Healthcare providers are increasingly converting to VNA platforms, as
Slide 7: Market Position
MARKET POSITION Mach7 is well positioned in the market to add new customers and upsell to existing install base Mach7 is able to win contracts because of: Best-in-class technology (IDC award) Strong customer references from well-known, leading healthcare centres e.g. Sentara, Massachusetts Gener
Slide 8: Revenue Model
REVENUE MODEL Mach7 is shifting to recurring and scalable revenue model Traditional capital, upfront software license fee, model giving way to monthly subscription revenue model Customer pays based on monthly usage – procedure volume Typical initial contract term is 5 years – predictive revenue
Slide 9: Capital Raising Overview
CAPITAL RAISING OVERVIEW Mach7 announced a successful A$9.0m placement on 16 November 2016 Overview Use of funds A$m % Two tranche placement raising A$9.0m from sophisticated and Expansion capital including sales and institutional investors, existing private lenders and Mach7 Directors and 1 marke
Slide 10: Key FY16 Financials
KEY FY16 FINANCIALS Pro-forma financials demonstrate strong traction FY16 FY16 Profit & loss (pro-forma) Pro-forma revenue was A$5.8m, which reflects what the group would (US$) (A$) Revenue $4.2m $5.8m have earned if the acquisition of Mach7 Enterprise Imaging Platform Cost of sales $0.5m $0.7m ha
Slide 11: Outlook for 2017
OUTLOOK FOR 2017 Mach7 expects significant revenue growth and to achieve profitability in the coming year We are optimistic about our outlook for the following reasons: Increasing participation in project tenders Proven technology for regional and national health information exchange projects
Slide 12: Disclaimer
DISCLAIMER Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should
Mach7 Technologies — Shareholder Meeting (December 2016) on 6ix